Clinical Trial Update: Study of rSIFN-co for Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of rSIFN-co for advanced solid tumors has been terminated, involving malignancies including melanoma, kidney cancer, lung cancer, color…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Kidney Cancer
• Lung Cancer
• Melanoma
• Neuroendocrine Tumor
• Prostate Cancer

Drugs mentioned

• rSIFN-co

Snippet

Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Conditions: Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor | Phase 1 | Status: TERMINATED